Clinical trials
Terminated Major Depressive Disorder trials with no applicable phase
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
51 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 1 |
| 2008 | 5 |
| 2010 | 4 |
| 2011 | 1 |
| 2012 | 2 |
| 2013 | 4 |
| 2014 | 4 |
| 2015 | 2 |
| 2016 | 3 |
| 2017 | 5 |
| 2019 | 5 |
| 2020 | 2 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 51 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Emory University | 2 |
| Icahn School of Medicine at Mount Sinai | 2 |
| Laureate Institute for Brain Research, Inc. | 2 |
| Paul E. Croarkin | 2 |
| The University of Texas Health Science Center at San Antonio | 2 |
| University Hospital, Montpellier | 2 |
| University of Manitoba | 2 |
| University of Michigan | 2 |
| Abbott Medical Devices | 1 |
| Ad scientiam | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Major Depressive Disorder | 51 |
| Depressive Disorder | 8 |
| Anxiety Disorders | 3 |
| Bipolar Disorder | 3 |
| Mood Disorders | 3 |
| Depressive Disorder, Treatment-Resistant | 2 |
| Stress Disorders, Post-Traumatic | 2 |
| Cognitive Dysfunction | 1 |
| Communicable Diseases | 1 |
| Dysthymic Disorder | 1 |
Trials
Showing 1 to 25 of 51. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.